Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Sanofi trumpets Darzalex rival isatuximab in refractory myelomaSanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share XSanofi trumpets Darzalex rival isatuximab in refractory myelomahttps://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
MacroGenics looks to future with breast cancer drug margetuximabA small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its Share XMacroGenics looks to future with breast cancer drug margetuximabhttps://pharmaphorum.com/news/macrogenics-looks-to-future-with-breast-cancer-drug-margetuximab/
AZ/Merck & Co wow ASCO with pancreatic cancer dataFinding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the Share XAZ/Merck & Co wow ASCO with pancreatic cancer datahttps://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/
Novartis steals a march in CDK4/6 market with breast cancer dataNovartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in Share XNovartis steals a march in CDK4/6 market with breast cancer datahttps://pharmaphorum.com/news/novartis-market-breast-cancer-data-asco-2019/
AZ/Merck & Co reveal data supporting PARP drug in prostate cancerPARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest Share XAZ/Merck & Co reveal data supporting PARP drug in prostate cancerhttps://pharmaphorum.com/news/az-merck-co-reveal-data-supporting-parp-drug-in-prostate-cancer/
J&J unveils early-stage prostate cancer data from Erleada at ASCOJohnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients Share XJ&J unveils early-stage prostate cancer data from Erleada at ASCOhttps://pharmaphorum.com/news/jj-unveils-early-stage-prostate-cancer-data-from-erleada-at-asco/
Epizyme files tazemetostat, seeking first okay in rare cancerEpizyme has filed for accelerated FDA approval of tazemetostat for advanced epithelioid sarcoma (ES), a rare form of Share XEpizyme files tazemetostat, seeking first okay in rare cancerhttps://pharmaphorum.com/news/epizyme-files-tazemetostat-rare-cancer/
Dynavax cuts staff and cancer R&D, focuses on vaccineUS biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down Share XDynavax cuts staff and cancer R&D, focuses on vaccinehttps://pharmaphorum.com/news/dynavax-cuts-staff-and-cancer-rd-focuses-on-vaccine/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
Amgen offers $167m for drug discovery biotech NuevolutionAmgen has agreed to buy Swedish biotech Nuevolution for around $167 million to boost its drug pipeline after Share XAmgen offers $167m for drug discovery biotech Nuevolutionhttps://pharmaphorum.com/news/amgen-offers-167m-for-drug-discovery-biotech-nuevolution/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
Morphosys to take on CAR-Ts in NHL with promising antibodyGermany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a Share XMorphosys to take on CAR-Ts in NHL with promising antibodyhttps://pharmaphorum.com/news/morphosys-to-take-on-car-ts-in-nhl-with-promising-antibody/
